Oculgen
China - Nanshan DistrictBiotechnology
Focus: Oculgen is a China-based biotechnology company founded in 2022 specializing in gene and cell therapies, biologics, and vaccines. The company operates in a highly competitive space with focus on infectious diseases and vaccines.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Open Jobs
0
About Oculgen
AI assessmentNot HiringNo open roles listed right now. Follow Oculgen to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
bispecific anti-VEGF and anti-complement
Adults With Neovascular Age-related Macular DegenerationClinical Trials (1)
NCT07520318This is a 96-week, Multicenter Study in Patients With Neovascular AMD That Evaluates OCUL101 for Efficacy, Safety, Durability, and Pharmacokinetics, Comparing it With Another Treatment. The Study Will be Conducted in Two Parts, Part A and Part B.
Phase 2/3Help build intelligence for Oculgen
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.